Background: Given the distinct biological characteristics and regional distribution of nasopharyngeal carcinoma (NPC) compared with other head and neck cancers, and uncertainties regarding therapeutic strategies, physicians require high-quality clinical practice guidelines (CPGs) to provide transparent recommendations for NPC treatment. This study aimed to critically appraise the quality of NPC CPGs and assess the consistency of their recommendations. Methods: We identified CPGs that provided recommendations on the diagnosis and management of NPC published up to December 2015. Four investigators independently appraised CPG quality using the Appraisal of Guidelines for Research & Evaluation (AGREE) II instrument. Key recommendations by CPGs were also evaluated. Results: A total of 7 CPGs were eligible for this study: 5 produced by professional organizations or governmental agencies and 2 were developed based on expert consensus. Of the 6 AGREE II domains, the applicability domain scored consistently low across CPGs (range, 13.5%-30.2%); no CPG achieved a score of >50% in all 6 domains. The scope and purpose domain (≥73.6% for 4 CPGs) and editorial independence domain (≥75.0% for 6 CPGs) scored highest. Of the 23 AGREE II items, 9 scored less than half of the points available in all 7 CPGs. The recommendations by CPGs were consistent in general; heterogeneity mainly existed among recommended therapeutic strategies. Conclusions: Variation exists in NPC CPG development processes and recommendations. Increased efforts are required to make comprehensive resources available to guide healthcare providers and enhance delivery of high-quality, evidence-based care for NPC. International collaboration is necessary to enable the development of high-quality and regionally relevant CPGs for NPC. J Natl Compr Canc Netw 2017;15(3):336-344 Because of increasing pressure to provide evidencebased medical care and increasing healthcare costs, 1 clinical practice guidelines (CPGs) have been increasingly used over the past decade worldwide.
Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma
approaches to high-quality care. However, it has been suggested that the quality of many published CPGs is unsatisfactory and that substantial heterogeneity exists among guideline recommendations. 2, 5, 6 Additionally, clinicians' lack of adherence to CPGs may be a result of distrust in guideline development processes and recom-mendations. 7 Therefore, systematically developed guidelines providing transparent recommendations are required.
The Appraisal of Guidelines for Research & Evaluation (AGREE) instrument is a validated, generic tool for the systematic appraisal of CPG methodological development and quality. 8 The AGREE project was established in 1998 by a group of international guideline developers and researchers; the original AGREE instrument was published in 2003 and the updated AGREE II instrument was released in 2010. 8 AGREE has become the standard tool for evaluation and development of CPGs, with the aim of improving guideline quality and likelihood of broad endorsement. [9] [10] [11] Nasopharyngeal carcinoma (NPC) is a unique head and neck (H&N) cancer with an uneven distribution: the age-standardized incidence rate ranges from 20 to 50 per 100,000 men in southern China to 0.5 per 100,000 in mainly Caucasian populations. 12 Despite originating from similar cell or tissue lineages, NPC is distinct to other epithelial H&N tumors. Radiotherapy (RT) is the primary and only curative modality, and combined chemoradiotherapy (chemoRT) is a pivotal treatment for locoregionally advanced NPC. 13 However, the optimal protocols remain elusive. The value of adjuvant chemotherapy (AC) or neoadjuvant chemotherapy (NACT) in addition to concurrent chemoRT (CCRT) are uncertain 14, 15 ; these issues need to be addressed clearly using reliable and high-quality CPGs. However, the quality and recommendations of NPC CPGs have not been specifically evaluated. Therefore, we aimed to critically appraise the quality of CPGs for NPC using the AGREE II instrument and assessed the consistency of their recommendations.
Methods

CPG Selection
CPGs were defined as systematically developed statements aiming to assist practitioner and patient decisions regarding appropriate healthcare for specific circumstances. 16 We focused on CPGs providing recommendations on NPC diagnosis and management published in English. When >1 set of documents was produced by the same organization, the most up-to-date version was considered. We excluded guidelines that (1) focused exclusively on H&N cancer without specific recommendations for NPC; (2) focused entirely on unique techniques, such as RT planning; and (3) concentrated only on recurrent or metastatic NPC.
Two reviewers (Y.P.C. and L.C.) identified relevant studies using keyword searches of MEDLINE, ESMO, NCCN, NCI, National Guideline Clearinghouse (NGC), Cancer Care Ontario, the National Institute for Health and Care Excellence, the Scottish Intercollegiate Guidelines Network, and the Guidelines International Network. The following terms were used: "nasopharyngeal neoplasm," "nasopharyngeal tumors," or "nasopharyngeal cancers," and "clinical practice guidelines," "recommendations," or "consensus." The last search was performed in December 2015.
CPG Data Extraction
For each CPG, 2 reviewers (Y.P.C. and L.C.) independently collected guideline characteristics (eg, year of publication, authoring organization, country or region, level of development, funding source, whether it is distinct to H&N cancer), and key recommendations stated (eg, recommendations on diagnosis, management, and/or surveillance of NPC). The individually recorded details were compared, and any disagreement was resolved by consensus.
Quality Assessment
The quality of each CPG was assessed using the AGREE II instrument, 8 which is composed of 23 items in 6 quality domains: (1) scope and purpose, (2) stakeholder involvement, (3) rigor of development, (4) clarity of presentation, (5) applicability, and (6) editorial independence (Table 1) . Each item is scored on a 7-point Likert scale (7=strongly agree; 1=strongly disagree). Four investigators (Y.P.C., L.C., W.F.L., and Y.S.) independently appraised all selected CPGs while blinded to each other's ratings; these investigators are all experienced in the multimodality treatment for NPC. Chance-adjusted interrater agreements were calculated independently for each item using Cohen's κ statistics. 17 Agreement was poor if κ≤0.2; fair if 0.2<κ≤0.4; moderate if 0.4<κ≤0.6; substantial if 0.6<κ≤0.8; good if κ>0.8; and perfect if κ=1. The mean score (range, 1-7) for each item was calculated from the 4 investigators' scores. Standardized scores (range, 0%-100%) for each domain were calculated by The standardized scores for each domain and mean values for the 23 items were compared. Key recommendations stated were also compared in a descriptive manner. All statistical analyses were performed using STATA software, Version 12 (STATA Corp, College Point, TX).
Results
Characteristics of Selected CPGs
Eligible CPGs ( [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] ; their characteristics are summarized in Table 2 . All guidelines were published between 2012 and 2015. Two were developed in multiple countries: APHNCEP was approved in the Asia and Pacific area 18 and ESMO in Europe. 20 The remaining CPGs were produced in China, 19 the United States, [24] [25] [26] [27] or Spain. 24 A total of 5 guidelines were produced by professional organizations or governmental agencies, and funded by specialty societies or government [20] [21] [22] [23] [24] [25] [26] [27] [28] ; 2 were produced by expert consensus, receiving funding from industry. 18, 19 Four guidelines provided distinct recommendations for NPC compared with other H&N cancers. 20, [26] [27] [28] 
CPG Appraisal
The domain scores (%) for each CPG, as assessed using the AGREE II instrument, are shown in Figure 2 and Table 3 . Of the 6 domains, applicability (domain 5) scored consistently low across CPGs (range, 13.5%-30.2%); no CPG scored >50% in all 6 domains. Scope and purpose (domain 1; ≥73.6% for 4 CPGs) and editorial independence scored highest (domain 6; ≥75.0% for 6 CPGs). With the exception of domain 5, a total of 4 NPC CPGs scored >50% in the remaining 5 domains: APHNCEP (range, 50.0%-86.1%), NCCN (range, 51.6%-87.5%), NCI (range, 56.3%-85.4%), and NGC (range, 62.5%-97.2%). NGC scored highest on domains 1 and 3 (97.2% and 70.3%), and NCCN and NCI scored highest on domain 2 (both, 66.7%). NCCN also ranked first on domain 6 (87.5%), ESMO scored highest on domain 4 (87.5%), and CHNCEP scored highest on domain 5 (30.2%). Table 1 presents the mean scores and standard deviations for the 23 items for each CPG. A substantial, good, or perfect agreement was observed for all items. On averaging the item scores for each of the 7 CPGs, 9 items scored fewer than half of the points available (<3.5); the most frequently poorly reported items were items 5, 7, 8, 13, 14, and 18 to 21 (Table 3) . Unsurprisingly, the mean scores for all CPGs were low for items in domain 5 (items 18-21), indicating that applicability did not attract enough attention and was performed poorly (Table 3 ). The mean scores for items 5 (range, 2.00-3.00) and 13 (range, 2.00-5.50) were low, indicating that the guidelines seldom provide the views or preferences of the target population, or were externally reviewed by experts before publication. The remaining items with low scores (items 7, 8, and 14) were in domain 3 (rigor of development) and were covering evidence searching, selection methods, and procedures for updating the guideline.
Key Recommendations of Guidelines
Supplemental eTable 1 (available with this article at JNCCN.org) presents the key recommendations 18 and CHNCEP 19 focus on additional cetuximab. The agents recommended were relatively consistent for concurrent chemotherapy and AC, but inconsistent for NACT. For metastatic NPC, platinum-based combination chemotherapy was the most common basic therapeutic scheme, whereas individualized combinations of surgery, RT, and chemotherapy were recommended for recurrent NPC.
CHNCEP, 19 NCCN, 24 NGC, 26 and SEOM 27 clearly define the interval and duration of surveillance. Only APHNCEP, 18 CHNCEP, 19 NCCN, 24 and NCI 25 consider monitoring of EBV DNA after treatment.
Discussion
This study sought to assess the quality and consistency of recommendations in CPGs involving the diagnosis and management of NPC, to assist clinicians when selecting appropriate guidelines. Using the AGREE II instrument, CPGs achieved consistently low scores in applicability (domain 5). The guidelines developed by APHNCEP, NCCN, NCI, and NGC achieved scores >50% in the remaining 5 domains. Of the 23 AGREE II items, 9 were inadequately reported. Additionally, heterogeneity in treatment recommendations exists.
Developers of CPGs often fail to meet widely endorsed standards devised to ensure high-quality guidelines. 29, 30 Although oncology guidelines appear to be of better quality than those of other diseases in certain domains of guidelines, 31 Reames et al 29 found the vast majority of oncology CPGs failed to adhere to the Institute of Medicine's standards for trustworthy guideline development. Moreover, significant variation in CPG development processes and recommendations were reported for specific oncology subspecialties. 11, 32 Much work remains to make oncology guidelines as methodologically sound and evidencebased as possible. This analysis shows that current CPGs for NPC also vary in methodological quality and have inconsistent recommendations. Considering the specific biological and regional characteristics of NPC compared with other H&N cancers, it is important to improve the quality and consistency of NPC CPGs to guide high-quality, evidence-based cancer care.
AGREE II enables the systematic evaluation of CPG quality and has been validated and endorsed by WHO as an accepted standard for guideline development. 33, 34 Based on the rationale that a high methodological quality reflects CPG integrity, reproducibility, and transparency, we also assessed guideline development methods. Methodological quality was optimal for "scope and purpose" and "editorial independence," (domains 1 and 6, respectively) whereas "applicability" (domain 5) received the lowest scores. In terms of individual items, applicability domain items (items 18-22) were of low quality, as expected. Additionally, most guidelines lacked explicit statements on whether the views and preferences of the target population were sought (item 5), whether the guideline had been externally reviewed by experts before publication (item 13), and the procedure for updating the guideline (item 14). Search methods and selection criteria (items 7 and 8) in for rigor of development (domain 3) were also inadequately reported. Lack of applicability may indicate that, despite investment of vast resources during development, little consideration is given to translation of CPG recommendations into practice.
For a guideline to be effective, it should take resource implications into account, describe potential facilitators and barriers, and provide clear advice on implementation. More effort is needed to improve conceptualization of implementation during development. Because patients may not have the same views as CPG developers on the outcomes they care most about (eg, severe side effects vs survival benefits), it is important to consider the views and preferences of patients. Similarly, opinions from external experts are also important to ensure validity. The low scores for these 2 items may be explained by the difficulties in or lack of resources available for involving patients or external experts in guideline development. Certain items in the rigor of development domain (domain 3; items 7, 8, and 13) may not attract enough attention; these methodological aspects are often adequately performed, despite not being reported. 35 Overall, the high-scoring items may correspond to aspects of development that are generally accepted and respected by various organizations. It is important for future projects, training, and other initiatives for CPG development to target the aspects corresponding to the low-scoring items to improve the overall methodology and quality of NPC guidelines.
Despite the differences in the rigor of development domain scores, the recommendations of the CPGs were generally consistent in terms of diagnosis and follow-up for NPC. All guidelines advocated biopsy of the primary site for diagnosis. However, only 3 guidelines (NCCN, ESMO, SEOM) provided recommendations on neck biopsy, and no firm recommendations were made. EBV DNA testing is of clinical significance for its valid effects on diagnosis, risk stratification, prognostication, and relapse supervision for NPC. 36 Only APHNCEP, ESMO, NCCN, and NCI recommend both pretreatment and posttreatment EBV DNA testing. For surveillance of NPC after treatment, NCCN provides relatively detailed recommendations.
Major distinctions across CPGs are mainly related to therapeutic strategies of combined chemoRT. RT alone and CCRT with or without AC were the main choices for stage II NPC. Although the phase III trial by Chen et al 37 found that CCRT provides a considerable survival benefit in stage II NPC, these patients underwent conventional 2-dimensional RT. As the advent of intensity-modulated RT (IMRT) has improved locoregional control and resulted in improved treatment outcomes, the benefit offered by additional chemotherapy is speculated to be smaller in patients treated with IMRT. 38, 39 This may explain why some CPGs recommended RT alone or CCRT without AC for stage II NPC. For locoregionally advanced NPC, CCRT is the basic therapeutic regimen; short-term evaluation of the phase III trial by Chen et al 40 found that additional AC did not significantly improve survival. However, NCCN still prefers CCRT plus AC for locoregionally advanced NPC, whereas APHNCEP, ESMO, NGC, and SEOM prefer CCRT alone. ESMO indicates that the efficacy of additional AC remains uncertain and that potential benefits and side effects should be considered. 20 Moreover, the efficacy of additional NACT followed by CCRT has not been confirmed, and was recommended in some cases based on individualized factors (APHNCEP), in patients with problematic RT planning (ESMO), or in highly symptomatic patients (SEOM); however, NACT should not negatively affect the optimal administration of CCRT (ESMO) in any case. 18, 20, 28 The value of additional AC and NACT require further research. Therapeutic approaches for metastatic/ recurrent NPC were inconclusive, and combinations of RT, chemotherapy, and/or surgery were advised based on the specific condition of each patient. Generally speaking, both NCCN and ESMO do well in their recommendations regarding the diagnosis and staging, and follow-up for NPC. In terms of treatment for NPC, the optimal combined chemoRT strategies remain inconclusive, and inconsistency among CPGs may result from variations in processes for selecting evidence, and methods of interpreting data and formulating recommendations.
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Use of AGREE II to evaluate methodologic quality depends on complete reporting of the guideline development process. 41 We evaluated the methodologic quality of the CPG publications, which are the most accessible to end-users, rather than the entire spectrum of guideline documents (eg, consensus statements containing specific policies and procedures for guideline development). If such complementary documents were not readily identifiable from the appraised CPG or its Web site, they were not assessed. For example, the ESMO guideline is a relatively brief summary compared with other guidelines, which may explain its relatively low scores. Although the supplementary materials represent a potentially valuable resource, these documents were not cited in the publications and the end user was not informed about these statements or their contents. 32, 35 Supplementary materials should be referenced and made more accessible in future versions to help users better understand how the guidelines were developed and increase trust in the recommendations. Moreover, explicit reporting of a guideline does not guarantee optimal recommendations; it is possible that a well-reported guideline contains defective recommendations. Conversely, a guideline that is not reported comprehensively or developed systematically may provide sound, evidence-based advice. Still, based on our results, we found that the NCG and NCCN guidelines received relatively high scores in development quality, whereas the NCCN and ESMO guidelines provided fairly practical recommendations. Therefore, generally NCCN recommendations may be a good choice to follow in clinical practice. However, it should be noted that no guideline is completely satisfactory, and some guidelines may be more suitable for the clinical practice in certain regions.
There are several limitations in this study. First, we relied on materials reported in published CPGs; reporting quality could affect these findings, which potentially places reporting quality under scrutiny. Secondly, AGREE II was used to evaluate CPGs as a whole, and is not specific for individual recommendations within guidelines. However, a global appraisal of the guideline development process may reflect the validity of the recommendations to a certain extent. Finally, only CPGs written in English were included; guidelines in other languages may play an important role in guiding clinical practice in local regions.
Because NPC is relatively rare and has an extremely unbalanced geographic distribution, it is necessary to promote international collaboration for guideline development and create CPGs with regional features. For example, guideline development organizations could share interpretation of evidence, while accounting for the organizational or cultural diversity of organizations and/or countries to provide insight into the challenges in different areas to adjust guideline recommendations accordingly. Through such efforts, development of high-quality, regionally relevant CPGs for NPC will be achieved.
Conclusions
Increased efforts are required to make comprehensive resources available to guide healthcare providers and enhance delivery of high-quality, evidence-based care for NPC. Guideline developers should evaluate both methodological processes and the resulting end product to improve quality.
